• Cancer Menu Update Banner

    JAMA Oncology Study on Paired DNA/RNA Testing Shows Clinical Impact to 1,000s of Patients

    The cumulative impact of RNA sequencing increases positive rate and decreases VUS rate

    Learn More
  • Cancer Menu Update Banner

    Don't take "negative"
    for an answer

    There's more to exome testing

    Learn More
  • Cancer Menu Update Banner

    SEER Observational study of 1.3 million cancer patients

    Ground-breaking study shows low rates of germline testing in cancer patients especially among Asian, Black, and Hispanic patients.

    Learn More
  • Cancer Menu Update Banner

    New Genetics in Medicine Publication

    demonstrates a 10% lower rate of VUS with WES/WGS compared to panels

    Learn More
  • Clinical Genomics Research Round-Up: Expert Snapshots of 10 Impactful Publications of 2023
  • Now Available
    RNAinsight Logo
    Expanded Coverage
    with up to 91 Genes

STAY INFORMED OF AMBRY UPDATES!

Sign up for our newsletter and be in the know.
Award for the best company for women in 2020 Award for the best company culture in 2020

Who We Are

With over 20 years of scientific innovations and discoveries, Ambry is an industry leader enabling healthcare professionals to confidently make informed care decisions with their patients by providing them with advanced genetic testing solutions.

At Ambry, people are at the center of our advancements, which starts with our own team. Recognized as an award-winning and outstanding place to work, we maintain a commitment to fostering diverse knowledge and perspectives to drive meaningful collaboration and help us all strive toward better health.

Join Our Team

Search Results

Start your search...